Corventis’s inaugural product, the Avivo mobile patient management system, has received the FDA’s clearance and is now commercially available for use by clinicians within and outside the US.
The company said that its platform technology is designed to deliver focused visibility into the cardiac health status of patients by combining patient-friendly wearable sensors with advanced computational algorithms, global wireless capabilities and a comprehensive web-based infrastructure.
According to Corventis, the system provides clinicians actionable information on an exception basis to help diagnose potential health risks, including non-lethal arrhythmias, from anywhere across the globe.
Ed Manicka, president and CEO of Corventis, said: “We are very proud of our accomplishments to date, including filing more than 50 patents internationally, deploying our solutions around the globe, successful enrollments in our clinical program and receiving this FDA clearance for our technology. The elegant solution we have developed will serve as a platform for multiple future products designed to improve the way heart conditions are managed.”